State Board of Administration of Florida Retirement System Buys 5,310 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI)

State Board of Administration of Florida Retirement System boosted its holdings in BioXcel Therapeutics, Inc. (NASDAQ:BTAIGet Rating) by 45.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 17,112 shares of the company’s stock after purchasing an additional 5,310 shares during the quarter. State Board of Administration of Florida Retirement System owned approximately 0.06% of BioXcel Therapeutics worth $226,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in BioXcel Therapeutics by 330.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 125,280 shares of the company’s stock valued at $2,620,000 after buying an additional 96,180 shares during the period. State Street Corp increased its stake in BioXcel Therapeutics by 4.1% in the first quarter. State Street Corp now owns 1,400,753 shares of the company’s stock worth $29,290,000 after purchasing an additional 55,657 shares during the period. Jane Street Group LLC increased its stake in BioXcel Therapeutics by 232.8% in the first quarter. Jane Street Group LLC now owns 78,004 shares of the company’s stock worth $1,631,000 after purchasing an additional 54,562 shares during the period. Bank of America Corp DE increased its stake in BioXcel Therapeutics by 38.6% in the first quarter. Bank of America Corp DE now owns 195,363 shares of the company’s stock worth $4,085,000 after purchasing an additional 54,378 shares during the period. Finally, DAVENPORT & Co LLC increased its stake in BioXcel Therapeutics by 154.3% in the second quarter. DAVENPORT & Co LLC now owns 85,670 shares of the company’s stock worth $1,131,000 after purchasing an additional 51,988 shares during the period. 45.32% of the stock is currently owned by institutional investors.

BioXcel Therapeutics Stock Down 4.6 %

BioXcel Therapeutics stock opened at $14.49 on Tuesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 10.34 and a quick ratio of 10.28. BioXcel Therapeutics, Inc. has a 12 month low of $8.80 and a 12 month high of $26.25. The stock has a market capitalization of $406.04 million, a PE ratio of -2.96 and a beta of 1.24. The business has a 50 day simple moving average of $12.32 and a 200-day simple moving average of $13.13.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BTAI. Canaccord Genuity Group increased their target price on BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, November 11th. Canaccord Genuity Group increased their price target on BioXcel Therapeutics from $75.00 to $76.00 and gave the stock a “buy” rating in a research report on Friday, November 11th. HC Wainwright dropped their price objective on BioXcel Therapeutics from $110.00 to $85.00 and set a “buy” rating on the stock in a research report on Wednesday, August 24th. Mizuho dropped their price objective on BioXcel Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research report on Friday, November 11th. Finally, Guggenheim lowered their price target on BioXcel Therapeutics from $28.00 to $25.00 and set a “buy” rating for the company in a report on Friday, November 11th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, BioXcel Therapeutics has a consensus rating of “Buy” and an average target price of $57.00.

Insider Buying and Selling

In related news, Director Krishnan Nandabalan sold 27,450 shares of the business’s stock in a transaction that occurred on Thursday, November 10th. The stock was sold at an average price of $15.00, for a total transaction of $411,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 37.00% of the stock is owned by company insiders.

About BioXcel Therapeutics

(Get Rating)

BioXcel Therapeutics, Inc is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Recommended Stories

Want to see what other hedge funds are holding BTAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics, Inc. (NASDAQ:BTAIGet Rating).

Institutional Ownership by Quarter for BioXcel Therapeutics (NASDAQ:BTAI)

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.